Audit of use of stiripentol in adults with Dravet syndrome

Audit of use of stiripentol in adults with Dravet syndrome

OBJECTIVES There are very few data available in the literature on the use of stiripentol in adults with Dravet syndrome (DS). DS cases are increasingly recognized in adulthood, and more children with DS now survive to adulthood. The aim of the study was to document the effectiveness and tolerability of stiripentol in adults with DS. MATERIAL AND METHODS We conducted an observational clinical ...

Stiripentol in Dravet syndrome: results of a retrospective U.S. study.

PURPOSE To review the efficacy and tolerability of stiripentol in the treatment of U.S. children with Dravet syndrome. METHODS U.S. clinicians who had prescribed stiripentol for two or more children with Dravet syndrome between March 2005 and 2012 were contacted to request participation in this retrospective study. Data collected included overall seizure frequency, frequency of prolonged seiz...

Stiripentol for dravet syndrome: is it worth it?

Acute hepatic injury in a child with Dravet syndrome: No protective effect of stiripentol

We read with interest the article by Nicolai et al. who described four children with Dravet syndrome treated with valproic acid (VPA) and topiramate (TPM), who all developed transient hepatic injury shortly after introduction of acetaminophen in therapeutic dosage. Based on the time interval between fever, administration of acetaminophen, epileptic status and liver enzyme disturbances, the auth...

Efficacy of Stiripentol in Dravet Syndrome with or without SCN1A Mutations

BACKGROUND AND PURPOSE The aim of this study was to determine the effectiveness of stiripentol (STP) add-on therapy to valproate and clobazam in patients with Dravet syndrome (DS) according to the presence of mutations in the sodium channel alpha-1 subunit gene (SCN1A). METHODS We performed direct sequencing to analyze SCN1A mutations in 32 patients with clinically confirmed with DS, and clas...